Claims for Patent: 7,413,860

Summary for Patent: 7,413,860

Title:	Systemic carnitine deficiency gene and uses thereof
Abstract:	The gene responsible for systemic carnitine deficiency was found to be the OCTN2 gene involved in the transportation of organic cations. This invention enables tests for this disease by detecting whether or not the OCTN2 gene has a mutation. Furthermore, systemic carnitine deficiency can be treated using the normal OCTN2 gene and its protein.
Inventor(s):	Nezu; Jun-Ichi (Ibaraki, JP), Ose; Asuka (Ibaraki, JP)
Assignee:	Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)
Application Number:	10/940,500
Patent Claims:	1. A method of testing whether an individual's genome carries a mutant OCTN2 allele that, in the homozygous state, may result in systemic carnitine deficiency, the method comprising (a) identifying an individual suspected of carrying the mutant allele; and (b) analyzing a nucleic acid sample from the individual to determine the presence or absence of a mutation in (i) DNA encoding OCTN2 (SEQ ID NO:1) or (ii) OCTN2 genomic DNA (SEQ ID NO:5) or (iii) a sequence that regulates expression of SEQ ID NO:5, wherein the presence of the mutation in (i) or (ii) or (iii) indicates that the individual carries a mutant OCTN2 allele that, in the homozygous state, may result in systemic carnitine deficiency. 2. A method of testing for, a mutation in an OCTN2 allele, the method comprising: (a) providing a DNA sample from an individual; (b) providing a pair of amplification primers, each primer comprising at least 15 nucleotides, wherein the pair of primers amplifies at least a part of DNA encoding SEQ ID NO:1, SEQ ID NO:5 or a sequence that regulates expression of SEQ ID NO:5; (c) subjecting the sample to amplification with the pair of primers, thereby generating amplified DNA; and (d) analyzing the amplified DNA to determine whether or not the DNA sample comprises a mutation in an OCTN2 allele. 3. The method of claim 2, wherein step (d) comprises subjecting the amplified DNA to restriction fragment length polymorphism analysis. 4. The method of claim 2, wherein step (d) comprises subjecting the amplified DNA to PCR-single-strand conformation polymorphism (PCR-SSCP) analysis. 5. The method of claim 2, wherein step (d) comprises: subjecting the amplified DNA, and similarly amplified DNA from a healthy control to denaturant gradient gel electrophoresis (DGGE), and comparing the mobility of the individual's amplified DNA to the mobility of the control amplified DNA, where a difference in mobility indicates the presence of a mutation in an OCTN2 allele of the individual. 6. The method of claim 2, wherein the pair of primers is: TABLE-US-00001 OCN2 43 (5'-GCAGGACCAAGGCGGCGGTGTCAG-3', SEQ ID NO:6) and OCN2 44 (5'-AGACTAGAGGAAAAACGGGATAGC-3', SEQ ID NO:7); OCN2 25 (5'-AGATTTTTAGGAGCAAGCGTTAGA-3' SEQ ID NO:8) and OCN2 26 (5'-GAGGCAGACACCGTGGCACTACTA-3', SEQ ID NO:9); OCN2 27 (5'-TTCACACCCACTTACTGGATGGAT-3' SEQ ID NO:10) and OCN2 50 (5'-ATTCTGTTTTGTTTTGGCTCTTTT-3', SEQ ID NO:11); OCN2 31 (5'-AGCAGGGCCTGGGCTGACATAGAC-3', SEQ ID NO:12) and OCN2 32 (5'-AAAGGACCTGACTCCAAGATGATA-3', SEQ ID NO:13); OCN2 33 (5'-TCTGACCACCTCTTCTTCCCATAC-3', SEQ ID NO:14) and OCN2 34 (5'-GCCTCCTCAGCCACTGTCGGTAAC-3', SEQ ID NO:15); OCN2 35 (5'-ATGTTGTTCCTTTTGTTATCTTAT-3', SEQ ID NO:16) and OCN2 36 (5'-CTTGTTTTCTTGTGTATCGTTATC-3', SEQ ID NO:17); OCN2 37 (5'-TATGTTTGTTTTGCTCTCAATAGC-3', SEQ ID NO:18) and OCN2 40 (5'-TCTGTGAGAGGGAGTTTGCGAGTA-3', SEQ ID NO:19); or OCN2 41 (5'-TACGACCGCTTCCTGCCCTACATT-3', SEQ ID NO:20) and OCN2 42 (5'-TCATTCTGCTCCATCTTCATTACC-3', SEQ ID NO:21). 7. The method of claim 2, wherein the mutation comprises a deletion. 8. The method of claim 7, wherein the deletion comprises a deletion in exon 1. 9. The method of claim 8, wherein the deletion affects the initiation codon. 10. The method of claim 8, wherein the deletion comprises a deletion of 113 nucleotides. 11. The method of claim 2, wherein the mutation comprises an insertion. 12. The method of claim 11, wherein the insertion causes a frame shift. 13. The method of claim 11, wherein the insertion comprises an insertion of a cytidine residue in exon 1. 14. The method of claim 2, wherein the mutation comprises a nucleotide substitution. 15. The method of claim 14, wherein the substitution creates a stop codon. 16. The method of claim 14, wherein the substitution comprises a guanosine to adenosine substitution in the codon that encodes Trp.sup.132. 17. The method of claim 2, wherein the mutation comprises a mutation in an intron splice site. 18. The method of claim 17, wherein the mutation prevents proper splicing from occurring. 19. The method of claim 17, wherein the splice site is located in intron 8. 20. The method of claim 19, wherein the mutation is a guanosine to adenosine substitution in the 3' end of intron 8. 21. The method of claim 2, wherein the individual of (a) is suspected of carrying a mutation correlated with systemic carnitine deficiency. 22. The method of claim 2, wherein the mutation, if present on both OCTN2 alleles, is correlated with systemic carnitine deficiency.

Details for Patent 7,413,860

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2018-09-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2018-09-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2018-09-07